At close: December 13 at 4:00:01 PM EST
After hours: 7:43:44 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 4 | 8 | 8 |
| Avg. Estimate | -0.3 | -0.32 | -1.19 | -1.32 |
| Low Estimate | -0.36 | -0.38 | -1.24 | -1.48 |
| High Estimate | -0.27 | -0.27 | -1.13 | -1.13 |
| Year Ago EPS | -0.29 | -0.3 | -1.27 | -1.19 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 3 | 8 | 8 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.29 | -0.35 | -0.34 | -0.32 |
| EPS Actual | -0.29 | -0.3 | -0.31 | -0.28 |
| Difference | 0 | 0.05 | 0.03 | 0.04 |
| Surprise % | 0.74% | 13.22% | 8.74% | 12.91% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.3 | -0.32 | -1.19 | -1.32 |
| 7 Days Ago | -0.3 | -0.33 | -1.2 | -1.33 |
| 30 Days Ago | -0.32 | -0.35 | -1.28 | -1.38 |
| 60 Days Ago | -0.33 | -0.35 | -1.29 | -1.39 |
| 90 Days Ago | -0.34 | -0.35 | -1.3 | -1.36 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | 1 |
| Up Last 30 Days | 6 | 1 | 6 | 5 |
| Down Last 7 Days | 1 | -- | 1 | 1 |
| Down Last 30 Days | 2 | -- | 2 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TERN | -3.71% | -7.38% | 6.08% | -10.41% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 12/4/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 12/4/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 12/4/2024 |
| Maintains | HC Wainwright & Co.: Neutral to Neutral | 11/13/2024 |
| Initiated | Oppenheimer: Outperform | 10/31/2024 |
| Reiterates | BMO Capital: Outperform to Outperform | 9/16/2024 |
Related Tickers
ALT Altimmune, Inc.
9.03
+5.12%
GPCR Structure Therapeutics Inc.
31.25
-1.45%
CRVS Corvus Pharmaceuticals, Inc.
7.38
-8.66%
VKTX Viking Therapeutics, Inc.
47.03
-1.75%
KROS Keros Therapeutics, Inc.
18.83
+2.17%
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.3100
-11.40%
ANAB AnaptysBio, Inc.
15.59
+3.79%
APVO Aptevo Therapeutics Inc.
4.0900
-27.35%
MDGL Madrigal Pharmaceuticals, Inc.
304.50
+0.67%
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.6100
-5.78%